Flash BioSolutions
LAUNCHES GMP PRODUCTION
OF REVOLUTIONARY mrna technology for
next-generation vaccines and therapies 

FlashRNA® is a cutting-edge mRNA platform providing the highest possible level of safety as a ready-to-inject drug product and offering transformative potential in RNA vaccines as well as a wide range of cell and gene therapy applications. This safe technology promises to be a game-changer, enabling the next generation of medical treatments, particularly in the realm of infectious diseases.

The mRNA vaccine market is experiencing explosive growth, with projections indicating a compound annual growth rate of over 30% through 2030^[1]. This surge is driven by the success of COVID-19 vaccines and the expanding pipeline of mRNA vaccines for various infectious diseases, including influenza, Zika, and respiratory syncytial virus (RSV) ^[2].

FlashRNA^® is poised to play a key role in this rapidly evolving landscape. Its unique technology, inspired by nature’s own mechanisms for RNA transfer, offers unparalleled efficiency in mRNA delivery. This breakthrough could significantly enhance the development of vaccines against a wide array of pathogens, potentially revolutionizing our approach to infectious disease prevention and treatment ^[3].

“Our commitment to innovation and excellence in RNA technology is reflected in the launch of GMP production for FlashRNA^®,” said Christine Duthoit, CSO of Flash BioSolutions. “This milestone is a testament to the hard work and dedication of our development and transfer teams, as well as our operations and quality teams, whose joint efforts have made this achievement possible.”

Anne Deflisque, Business Director, added, “The start of industrial-scale GMP production is a critical step in bringing our groundbreaking solutions to market. With FlashRNA^®, we’re not just participating in the mRNA revolution – we’re helping to lead it. Our technology’s efficiency and versatility position us uniquely to address the growing demand for mRNA-based solutions in infectious disease control and beyond.”

Jérôme Bédier, CEO, concluded, “Flash BioSolutions is at the forefront of mRNA technology, and with FlashRNA^®, we are set to make a significant impact on the future of medicine. Our technology’s ability to vehicle RNA with unprecedented efficiency could accelerate the development of vaccines for challenging infectious diseases and improve global health outcomes. We congratulate our entire team for their exceptional work in reaching this pivotal moment.”